Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting fatty acid β-oxidation impairs monocyte differentiation and prolongs heart allograft survival
Yuehui Zhu, Hao Dun, Li Ye, Yuriko Terada, Leah P. Shriver, Gary J. Patti, Daniel Kreisel, Andrew E. Gelman, Brian W. Wong
Yuehui Zhu, Hao Dun, Li Ye, Yuriko Terada, Leah P. Shriver, Gary J. Patti, Daniel Kreisel, Andrew E. Gelman, Brian W. Wong
View: Text | PDF
Research Article Metabolism Transplantation

Targeting fatty acid β-oxidation impairs monocyte differentiation and prolongs heart allograft survival

  • Text
  • PDF
Abstract

Monocytes play an important role in the regulation of alloimmune responses after heart transplantation (HTx). Recent studies have highlighted the importance of immunometabolism in the differentiation and function of myeloid cells. While the importance of glucose metabolism in monocyte differentiation and function has been reported, a role for fatty acid β-oxidation (FAO) has not been explored. Heterotopic HTx was performed using hearts from BALB/c donor mice implanted into C57BL/6 recipient mice and treated with etomoxir (eto), an irreversible inhibitor of carnitine palmitoyltransferase 1 (Cpt1), a rate-limiting step of FAO, or vehicle control. FAO inhibition prolonged HTx survival, reduced early T cell infiltration/activation, and reduced DC and macrophage infiltration to heart allografts of eto-treated recipients. ELISPOT demonstrated that splenocytes from eto-treated HTx recipients were less reactive to activated donor antigen-presenting cells. FAO inhibition reduced monocyte-to-DC and monocyte-to-macrophage differentiation in vitro and in vivo. FAO inhibition did not alter the survival of heart allografts when transplanted into Ccr2-deficient recipients, suggesting that the effects of FAO inhibition were dependent on monocyte mobilization. Finally, we confirmed the importance of FAO on monocyte differentiation in vivo using conditional deletion of Cpt1a. Our findings demonstrate that targeting FAO attenuates alloimmunity after HTx, in part through impairing monocyte differentiation.

Authors

Yuehui Zhu, Hao Dun, Li Ye, Yuriko Terada, Leah P. Shriver, Gary J. Patti, Daniel Kreisel, Andrew E. Gelman, Brian W. Wong

×

Figure 6

Loss of Ccr2 in HTx recipients abrogates the effects of FAO inhibition.

Options: View larger image (or click on image) Download as PowerPoint
Loss of Ccr2 in HTx recipients abrogates the effects of FAO inhibition.
...
(A) Comparison of graft survival in vehicle-treated (ctrl-treated) or etomoxir-treated (eto-treated) BALB → B6 CCR2–/– heart allografts. There was no statistical difference in survival (P = 0.7698 by Mantel-Cox test). (B–E) Flow cytometric assessment in BALB → Ccr2–/– heart allografts 4 days after transplant, shown as a percentage of CD45+ cells (left graph) or live cells (right graph; data for live cells from BALB → B6 HTx is replotted from Figures 1 and 2). (B) Pan T cells assessed by CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB B6 Ccr2–/– HTx). (C) Activated T cells assessed by CD69+CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB →B6 Ccr2–/– HTx). (D) DCs assessed by CD11c+MHCII+CD64– cells (ctrl, n = 5; eto, n = 5 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB B6 Ccr2–/– HTx). (E) Macrophages assessed by CD11b+CD64+CD24– cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB → B6 Ccr2–/– HTx). (F) ELISPOT assay performed using splenocytes procured 4 days after transplantation from ctrl or eto-treated BALB B6 Ccr2–/– heart allografts. Samples were stimulated with donor-derived (BALB) APCs and assessed for the production of IFN-γ (ctrl, n = 5; eto, n = 5). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ****P < 0.0001 (B–E, left graphs, and F) by t test or (B–E, right graphs) ANOVA and Bonferroni’s post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts